Yoshinori Kato

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5372070/publications.pdf

Version: 2024-02-01

47 papers	2,331 citations	279798 23 h-index	214800 47 g-index
47 all docs	47 docs citations	47 times ranked	3559 citing authors

#	Article	IF	Citations
1	Quantification and tracking of genetically engineered dendritic cells for studying immunotherapy. Magnetic Resonance in Medicine, 2018, 79, 1010-1019.	3.0	17
2	Direct Cell Labeling to Image Transplanted Stem Cells in Real Time Using a Dualâ€Contrast MRI Technique. Current Protocols in Stem Cell Biology, 2017, 42, 5A.10.1-5A.10.19.	3.0	2
3	Endocan as a prognostic biomarker of triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 161, 269-278.	2.5	34
4	Non-Temperature Induced Effects of Magnetized Iron Oxide Nanoparticles in Alternating Magnetic Field in Cancer Cells. PLoS ONE, 2016, 11, e0156294.	2.5	27
5	Intrinsic Resistance to 5-Fluorouracil in a Brain Metastatic Variant of Human Breast Cancer Cell Line, MDA-MB-231BR. PLoS ONE, 2016, 11, e0164250.	2.5	11
6	A preclinical murine model for the early detection of radiation-induced brain injury using magnetic resonance imaging and behavioral tests for learning and memory: with applications for the evaluation of possible stem cell imaging agents and therapies. Journal of Neuro-Oncology, 2016, 128, 225-233.	2.9	8
7	Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models. Scientific Reports, 2016, 6, 24298.	3.3	31
8	Ganetespib radiosensitization for liver cancer therapy. Cancer Biology and Therapy, 2016, 17, 457-466.	3.4	12
9	Imaging transplanted stem cells in real time using an MRI dual-contrast method. Scientific Reports, 2015, 5, 13628.	3.3	51
10	Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer. Magnetic Resonance in Medicine, 2015, 74, 1556-1563.	3.0	94
11	Role of Apoptosis Signal-regulating Kinase 1 (ASK1) as an Activator of the GAPDH-Siah1 Stress-Signaling Cascade. Journal of Biological Chemistry, 2015, 290, 56-64.	3.4	18
12	Structure-Function Studies of the bHLH Phosphorylation Domain of TWIST1 in Prostate Cancer Cells. Neoplasia, 2015, 17, 16-31.	5.3	21
13	Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice. Pharmaceutical Research, 2015, 32, 3746-3755.	3.5	16
14	PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3. Cancer Chemotherapy and Pharmacology, 2015, 76, 821-827.	2.3	12
15	NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3. Oncotarget, 2015, 6, 29901-29913.	1.8	45
16	Heterogeneity of Tumor Vasculature and Antiangiogenic Intervention: Insights from MR Angiography and DCE-MRI. PLoS ONE, 2014, 9, e86583.	2.5	21
17	Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics. Biomaterials, 2014, 35, 2346-2354.	11.4	34
18	Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2014, 27, 161-170.	2.0	6

#	Article	IF	Citations
19	The Twist Box Domain Is Required for Twist1-induced Prostate Cancer Metastasis. Molecular Cancer Research, 2013, 11, 1387-1400.	3.4	79
20	Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biology and Therapy, 2013, 14, 347-356.	3.4	43
21	Natural <scp>D</scp>â€glucose as a biodegradable MRI contrast agent for detecting cancer. Magnetic Resonance in Medicine, 2012, 68, 1764-1773.	3.0	295
22	Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-Î±. Oncogene, 2012, 31, 3223-3234.	5.9	135
23	Efficacy of lactosaminated and intact N-succinyl-chitosan-mitomycin C conjugates against M5076 liver metastatic cancer. Journal of Pharmacy and Pharmacology, 2010, 54, 529-537.	2.4	15
24	Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique. Biomaterials, 2010, 31, 7132-7138.	11.4	31
25	Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopyâ€. Neuro-Oncology, 2010, 12, 71-79.	1.2	11
26	Monitoring of release of cargo from nanocarriers by MRI/MR spectroscopy (MRS): Significance of T₂/T effect of iron particles. Magnetic Resonance in Medicine, 2009, 61, 1059-1065.	3.0	19
27	Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Therapy, 2009, 16, 217-226.	4.6	73
28	Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biology and Therapy, 2007, 6, 891-897.	3.4	17
29	Intracellular Delivery of Nanocarriers for Cancer Therapy. Current Nanoscience, 2007, 3, 329-338.	1.2	12
30	Noninvasive1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magnetic Resonance in Medicine, 2006, 55, 755-761.	3.0	24
31	Twist Overexpression Induces In vivo Angiogenesis and Correlates with Chromosomal Instability in Breast Cancer. Cancer Research, 2005, 65, 10801-10809.	0.9	257
32	Contribution of chitosan and its derivatives to cancer chemotherapy. In Vivo, 2005, 19, 301-10.	1.3	32
33	Comparison of intraperitoneal continuous infusion of floxuridine and bolus administration in a peritoneal gastric cancer xenograft model. Cancer Chemotherapy and Pharmacology, 2004, 53, 415-422.	2.3	6
34	N-succinyl-chitosan as a drug carrier: water-insoluble and water-soluble conjugates. Biomaterials, 2004, 25, 907-915.	11.4	156
35	LactosaminatedN-succinyl-chitosan: Preparation and biodistribution into the intestine, bone, lymph nodes and male genital organs after I.v. administration. Macromolecular Research, 2003, 11, 382-386.	2.4	4
36	In vitro characteristics of liposomes and double liposomes prepared using a novel glass beads method. Journal of Controlled Release, 2003, 90, 71-79.	9.9	20

#	Article	IF	Citations
37	Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. Journal of Controlled Release, 2003, 89, 429-436.	9.9	50
38	In vivo efficacy of a novel double liposome as an oral dosage form of salmon calcitonin. Drug Development Research, 2003, 58, 253-257.	2.9	17
39	Double Liposomes: Hypoglycemic Effects of Liposomal Insulin on Normal Rats. Drug Development and Industrial Pharmacy, 2003, 29, 725-731.	2.0	39
40	Application of Chitin and Chitosan Derivatives in the Pharmaceutical Field. Current Pharmaceutical Biotechnology, 2003, 4, 303-309.	1.6	228
41	Preparation of novel double liposomes using the glass-filter method. International Journal of Pharmaceutics, 2002, 248, 93-99.	5.2	19
42	Enhancement of transdermal absorption by switching iontophoresis. International Journal of Pharmaceutics, 2002, 249, 81-88.	5.2	13
43	Depolymerization of N-succinyl-chitosan by hydrochloric acid. Carbohydrate Research, 2002, 337, 561-564.	2.3	20
44	Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis. International Journal of Pharmaceutics, 2001, 226, 93-106.	5.2	43
45	Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. Journal of Controlled Release, 2001, 70, 295-307.	9.9	102
46	Biological Fate of Highly-Succinylated N-Succinyl-chitosan and Antitumor Characteristics of Its Water-soluble Conjugate with Mitomycin C at I.v. and I.p. Administration into Tumor-Bearing Mice.. Biological and Pharmaceutical Bulletin, 2000, 23, 1497-1503.	1.4	25
47	Evaluation of N-succinyl-chitosan as a systemic long-circulating polymer. Biomaterials, 2000, 21, 1579-1585.	11.4	86